Unlocking HRR testing: Why it matters in mPC
Episode 1. Alicia Morgans and David Olmos discuss the evolving role of HRR testing in mPC, highlighting the striking aggressiveness of BRCA-mutated disease, even in patients with low-volume metastases. Their conversation examines the clinical importance of distinguishing germline from somatic mutations, the need for early testing and treatment escalation, and the practical challenges of implementing HRR testing across diverse healthcare settings. Insights from the CAPTURE study and recent trials underscore the importance of multidisciplinary collaboration and structured diagnostic pathways in making HRR testing clinically actionable. View transcript.
Chapters
00:50 How do HRRm shape mCRPC behavior?
03:07 CAPTURE study: Clinical insights
04:56 When should HRR be tested in mPC?
07:24 HRR testing: Germline vs somatic
10:12 Prognostic relevance of BRCA mutations
13:05 PROfound trial and PARP use in mCRPC
15:50 HRR testing in practice
18:27 Multidisciplinary HRR testing
20:47 Making HRR testing clinically actionable
Meet the guest speaker
David Olmos, MD, PhD
David Olmos is a Clinical Scientist and Medical Oncologist at Hospital Universitario 12 de Octubre and its research institute in Madrid, Spain, where he holds a tenured position as a Distinguished Researcher. Olmos has contributed to the development of several prostate cancer drugs.
Disclosures: Received multiple grants as Principal Investigator (PI) or Co-PI from AECC (Asociación Española Contra el Cáncer), CRIS (CRIS Cancer Foundation), DoD-CDMRP (U.S. Department of Defense – Congressionally Directed Medical Research Programs), ISCIII (Instituto de Salud Carlos III), PCF (Prostate Cancer Foundation), Ramón y Cajal Research Excellence Programme (Spanish Ministry of Science), and SEOM (Sociedad Española de Oncología Médica).
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.